filecrux
Oct 13, 9:46 PM
$AGMB Belgian fibro-inflammation biotech Agomab dosed the first patient in its ~320-patient Phase 2b of ontunisertib in fibrostenosing Crohn's, triggering a €7M payment to former Origo Biopharma holders. The €7M is about 2.8% of the €252.0 million in cash, cash equivalents and short-term cash investments Agomab held at June 30, 2026, which the company expects to fund operations into the first half of 2029. Payable so far: €10M of up to €20M; the rest needs further development and regulatory steps. Primary endpoint at Week 24; no readout date given.
0 replies